Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.47 AUD | +0.41% | -6.03% | -22.03% |
May. 28 | Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call | |
May. 27 | Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.03% | 1.65B | |
+46.14% | 754B | |
+40.95% | 630B | |
-5.84% | 352B | |
+19.99% | 331B | |
+9.65% | 298B | |
+18.45% | 250B | |
+11.88% | 217B | |
-0.78% | 216B | |
+6.00% | 164B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- Neuren Pharmaceuticals Narrows H1 Net Loss by 11%